(Q33392955)

English

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

author name string

Dok Hyun Yoon

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Min-Hee Ryu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Baek-Yeol Ryoo

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Moyeol Beck

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dae Ro Choi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoojin Cho

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jae-Lyun Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Heung-Moon Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tae Won Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoon-Koo Kang

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

819-827

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9593-1

21 January 2018

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/21104107

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9593-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33392955&oldid=2195316422"